[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zealand University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":705},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,50,76,105,151,184,210,243,273,295,319,345,368,400,420,448,477,506,533,554,584,604,627,659,684],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100565656",false,"NCT06645015","The AIDPRO-CRC Trial","AI-Driven Personalized Perioperative Management in Colorectal Cancer: A Randomized Controlled Clinical Trial - The AIDPRO-CRC Trial","AIDPRO-CRC","Inclusion criteria - patients\n\nTo be eligible for study participation, the following criteria must be met:\n\n* Histologically confirmed diagnosis or strong clinical suspicion of first-time colon or rectal cancer, clinical stage I-IV.\n* Signed written informed consent obtained prior to any study-specific procedures.\n* Age ≥18 years at the time of consent.\n* Scheduled for potentially curative surgery as determined by a multidisciplinary team (MDT) conference.\n* Availability of all required input variables for the AI model not directly assessed by the surgeon (e.g., ASA score, WHO performance status).\n\nExclusion criteria - patients\n\nA patient will be excluded from the study if:\n\n• Surgery with curative intent is no longer planned despite previous eligibility.\n\nHealthcare Professionals Surgeons and other healthcare professionals involved in the use of the AI-based platform will be invited to participate in two sub-studies: a user satisfaction survey and a simulation-based study. Eligible personnel will be automatically invited upon registration as platform users.\n\nInclusion criteria - healthcare professionals\n\nTo be eligible to participate in the survey and simulation study, individuals must:\n\n* Be licensed medical doctors.\n* Be either board-certified specialists in surgical oncology or currently in training to become one.\n\nExclusion criteria - healthcare professionals There are no exclusion criteria for participation in the survey or simulation study.","ALL","18 Years",{"count":20,"type":21},1200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The AIDPRO-CRC trial aims to improve outcomes for patients undergoing surgery for colorectal cancer by using artificial intelligence (AI) to assist surgeons in risk assessment. The trial will evaluate whether AI can help surgeons better predict the risk of complications and death, leading to improved care, fewer complications, and better use of healthcare resources.\n\nIn this nationwide, randomized clinical trial, participants will be divided into two groups. One group will have their risk assessed by a surgeon using standard clinical methods, while the other group will have their risk assessed by a surgeon using AI assistance. Based on the risk level, patients will receive varying levels of perioperative care. The AI-assisted risk assessment aims to tailor the treatment more precisely to each patient's individual needs, precisely allocating care to those who need it to more efficiently allocate heath system resources while having no deterioration in patient outcomes.\n\nThe primary hypothesis is that AI-assisted risk assessment will lead to more efficient and economic patient care without a deterioration in patient outcomes. The trial also aims to explore clinician satisfaction with the platform and its perceived effect. This is paired with a substudy exploring the variability of suggested treatment plans by clinicians with and without access to the MDT presentation platform.\n\nThe trial will include patients at seven hospitals across Denmark, involving patients diagnosed with colorectal cancer who are scheduled for curative surgery. All patients will receive standard treatment according to national guidelines, with the only difference being the modality of risk assessment. For the evaluation of the clinicians satisfactory with the device and the substudy of variability of suggested treatment plans, the trial will enroll clinicians using the device.\n\nThis study is a researcher-initiated, nationwide, randomized clinical trial involving patients diagnosed with colorectal cancer across eight hospitals in Denmark. Participants will be randomly assigned to one of two groups: AI-assisted risk assessment or standard surgeon-led assessment. The intervention focuses on optimizing perioperative care based on individual risk levels determined by either AI or the surgeon's clinical judgment.\n\nThe study builds on a successful pilot project (AID-SURG) that showed promising results in reducing complications, hospital stays, and readmissions.",[27],"Colo-rectal Cancer",[29,30,31,32,33,34,35,36],"Prehabilitation","AI","Artificial Intelligence","Risk-estimation","perioperative","Post-operative complications","Risk-stratification","Algorithm","RECRUITING","2026-05-28",{"date":40,"type":41},"2026-06-02","ACTUAL",{"date":43,"type":41},"2025-10-24",{"date":45,"type":21},"2028-02-01",{"name":47,"class":48},"Zealand University Hospital","OTHER",7,{"id":51,"slug":4,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100638260","NCT07573930","Metabolic Control in Anesthesia and Surgery","Deteriorated Metabolic Control in the Perioperative Period in Surgical Patients: What is the Impact of Anesthetic Preparation and Patient Frailty?","MACS","Inclusion Criteria:\n\n* Adult patients (≥18 years) scheduled for elective non cardiac surgery\n* Expected surgery duration \\>1 hour\n* Administration of dexamethasone as part of standard anaesthetic regimen or planned by the responsible anaesthetist to enhance recovery or to limit risk of PONV.\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Not possible to obtain consent or permission\n* Known allergy or adverse reaction to dexamethasone\n* Type 1 diabetes (due to need for insulin titration)\n* Active infection, sepsis, or immunosuppression\n* Contraindications to continuous glucose monitoring (CGM)",{"count":58,"type":21},100,"OBSERVATIONAL","The goal of this observational study is to investigate how a standard dose of the drug dexamethasone affects blood sugar levels during and after non-cardiac surgery in adult patients.\n\nThe main questions it aims to answer are:\n\n* How does dexamethasone influence blood sugar levels in patients undergoing non-cardiac surgery?\n* Does continuous glucose monitoring (CGM) provide a more accurate estimate of blood sugar fluctuations compared to traditional time-specific finger-prick measurements?\n\nParticipants are scheduled to receive dexamethasone as part of standard anesthesia care and will undergo their planned surgery. As part of the study, a continuous glucose monitoring (CGM) device will be placed on their upper arm approximately 12 hours before surgery and will remain in place for up to 10 days after the operation. During this period, their blood sugar levels will be measured using both the CGM device and traditional finger-prick tests. CGM readings are blinded for both participants and clinicians. No additional treatments or changes to their standard care will be made as a result of their participation in the study.\n\nThe study will include 100 adult patients from the Department of Anesthesiology at Sjællands University Hospital, Roskilde.",[62,63,64,65,66],"Anesthesia","Continuous Glucose Monitoring","Hyperglycemia Steroid-induced","Hyperglycemia Stress","Surgical Procedure, Unspecified","2026-05-04",{"date":69,"type":41},"2026-05-07",{"date":71,"type":41},"2026-04-23",{"date":73,"type":21},"2028-12-31",{"name":47,"class":48},1,{"id":77,"slug":4,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":75},"100459250","NCT05260177","Study on the Effect of 40 Hz Non-Invasive Light Therapy System","ALZLIGHT Stage III - Study on the Effect of 40 Hz Non-Invasive Light Therapy System","Inclusion Criteria:\n\n* Adult competent person, able to understand the nature of the study and give written informed consent.\n* Diagnosed with probable mild to moderate AD based on NIA-AA diagnostic criteria or in a prodromal stage of AD with at least one positive biomarker of AD.\n* Age \\> 40 years. Females must be post-menopausal.\n* Fluent in Danish.\n* \\> 8 years of normal school education\n* Pass a color-blindness test (Ishihara color test)\n* Have visual and auditory capabilities, and language skills necessary for neuropsychological testing.\n* Participants must have a designated caregiver, who is available to the participant and can provide the necessary assistance with using the LTS device and the Actigraph wearable at home and assist with clinical visits and other practical issues\n\nExclusion Criteria:\n\n* Profound visual impairment (visual acuity \\> 0.5) provided correction with spectacles, if needed\n* Significant abnormalities related to important parts of the brain, e.g., the visual system, prefrontal cortex, or hippocampus, or relevant lesions detected by pre-trial imaging.\n* Prior history of significant diseases related to the visual system or the brain.\n* Medication: Use of any antiepileptic drugs, neuromodulating drugs or high dose of sedatives will be excluded.\n* Prior history of substance abuse within the past 2 years.\n* Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol (at the discretion of the PI)","40 Years",{"count":84,"type":21},62,[24],"The ALZLIGHT STAGE III Study is a continuation of the ALZLIGHT Pilot - Study on Safety, Feasibility and Neural Activation of Non-Invasive Light Therapy System. As with the first two stages, this study will examine whether entrainment of 40 Hz neural oscillation by novel 40 Hz Invisible Spectral Flicker is a potential therapy for Alzheimer's Disease. In order to examine this, 62 patients with mild to moderate Alzheimer's Disease will be recruited. The patients will be exposed to the Non-Invasive Light Therapy System for 1 hour a day for 6 months. The effect will be measured by a combination of electroencephalography, cognitive testing, functional magnetic resonance imaging, magnetic resonance spectroscopy and actigraphy.",[88],"Alzheimer's Disease",[90,91,92,93,94,95,96,97],"Gamma Entrainment","40 Hz","Invisible Spectral Flicker","LED","Light Therapy","Brain Stimulation","Gamma Oscillations","Gamma Induction","2026-04-30",{"date":69,"type":41},{"date":101,"type":41},"2022-09-20",{"date":103,"type":21},"2028-12-01",{"name":47,"class":48},{"id":106,"slug":4,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":17,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":116,"conditions":117,"keywords":127,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":75},"100608375","NCT07200739","Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI)","Development of Deep Learning Models for Detection of Neurodegenerative Diseases Using Speech - a Danish Language-based Artificial Intelligence Study (DetectAI)","DetectAI","Inclusion Criteria:\n\nModel A (patient participants)\n\n* Age \\> 50 years\n* Fluent in Danish\n* Minimum of 7 years of schooling\n* A diagnosis of either MCI or AD, given at the SUH memory clinic within 6 months before enrollment\n\nModel A (cognitively healthy controls)\n\n* Age \\> 50 years\n* Fluent in Danish\n* Minimum of 7 years of schooling\n\nModel B:\n\n* Age \\> 50 years\n* Fluent in Danish\n* Minimum of 7 years of schooling\n\nExclusion Criteria:\n\nModel A:\n\nPatients:\n\n* Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis)\n* MMSE score \\\u003C 16\n* Concomitant diagnoses which are expected to influence cognitive impairment (eg. depression)\n* Patients unable to give consent\n* Patients with alcohol consumption \\>21 standard alcohol units per week\n* Any history of speech or language impairment predating the current condition\n\nCognitively healthy controls:\n\n* Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis)\n* MMSE \\\u003C 26 and ACE \\\u003C 90\n* Clinical, laboratory, or neuroradiological findings that could affect cognitive functions\n* Known diseases which are expected to impair cognitive functions\n* Any history of speech or language impairment predating the current condition\n* Patients with alcohol consumption \\>21 standard alcohol units per week.\n\nModel B:\n\n* Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis)\n* MMSE score \\\u003C 16\n* Patients unable to give consent\n* Patients with concomitant psychosis or severe psychiatric comorbidities other than depression\n* Any history of speech or language impairment predating the current condition",true,"50 Years",{"count":115,"type":21},440,"The goal of this observational study is to learn if an artificial intelligence (AI)-based speech analysis tool can identify which patients with memory problems need specialist evaluation at a memory clinic. The main questions it aims to answer are:\n\nCan the AI model accurately distinguish between patients who need referral to a memory clinic (those with dementia or Mild Cognitive Impairment) and patients who don't (those with normal cognition or memory problems from other causes like depression)? Which speech patterns and cognitive test features are most useful for making this distinction?\n\nResearchers will compare speech recordings and cognitive test results from patients diagnosed with dementia or MCI to those from patients with normal cognition or non-neurodegenerative cognitive impairment to see if the AI model can reliably predict who needs specialist dementia care.\n\nParticipants will:\n\nComplete standard cognitive tests at the memory clinic Perform structured speech tasks while being audio-recorded Receive their usual clinical evaluation and diagnosis from memory clinic specialists\n\nThe results of this study will help develop a tool that can assist doctors in making faster, more accurate decisions about which patients need specialist dementia evaluation, potentially leading to earlier diagnosis and better patient outcomes.",[118,119,120,121,122,123,124,125,126],"Dementia (Diagnosis)","Alzheimer Dementia (AD)","Vascular Dementia (VaD)","Lewy Body Dementia (LBD)","Frontotemporal Dementia (FTD)","Mild Cognitive Impairment (MCI)","Depression - Major Depressive Disorder","Stress","Cognitive Impairment",[128,129,130,131,132,133,134,135,136,121,122,123,137,138,139,140,126,141],"artificial intelligence","speech-based artificial intelligence","artificial intelligence in dementia diagnostics","artificial intelligence for dementia screening","artificial intelligence for dementia classification","speech based artificial intelligence","dementia","Vascular dementia (VaD)","Alzheimer dementia (AD)","Depression - Major Depressive disorder","Dementia (diagnosis)","machine learning","stress","deep learning","NOT_YET_RECRUITING","2026-04-28",{"date":145,"type":41},"2026-05-05",{"date":147,"type":21},"2026-06-01",{"date":149,"type":21},"2028-07",{"name":47,"class":48},{"id":152,"slug":4,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},"100628389","NCT07460999","Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC)","Effects and Mechanisms of Online Delivered Singing Training vs Usual Care in Patients With Persistent Symptoms 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) - a Multi-centre RCT","Sing-a-Lung 2","Inclusion Criteria:\n\nPatients who display persistent symptoms 6-18 months (+\u002F- one month) after surgical resection of localised lung cancer with video-assisted thoracoscopy (VATS) will be invited to participate in the study.\n\nInclusion criteria for the study include:\n\n1. Persistent symptoms, i.e., an EORTC-QLQ-C30 symptom domain score (in any item) of ≥2 (=\"clinically relevant symptom or problem that should have healthcare professional attention\"),\n2. Surgery for stage I lung cancer 6-18 months (+\u002F- one month) earlier,\n3. Motivated for participating in the project (and acceptance of randomisation procedure),\n4. Access to a computer or a tablet with internet access,\n5. Ability to speak and understand Danish,\n6. Acceptance of the scheduled times of the singing intervention twice a week.\n\nExclusion Criteria:\n\nExclusion criteria include:\n\n1. Unstable coronary diseases,\n2. Severe cognitive disabilities (e.g., dementia),\n3. Indication for adjuvant chemotherapy or other antineoplastic therapy,\n4. Signs of lung cancer recurrence at regular follow-up CT scan.\n\nNo previous singing experience or musical competence is required. Participants will be informed that they are allowed to participate in additional offer of structured or unstructured offer physical exercise training and\u002For singing along with the project.",{"count":58,"type":21},[24],"People who have undergone curative surgery for non-small cell lung cancer (NSCLC) often experience reduced quality of life (QoL), a high burden of symptoms, and physical deconditioning. Current Danish rehabilitation offers are heterogeneous and inconsistent and not tailored to the specific needs of this population. Additionally, some patients continue to suffer from persistent physical symptoms months or even years after surgery, yet no targeted support is currently available for them. Singing - delivered as a structured form of training - has shown benefits in improving both physical and psychological outcomes in individuals with chronic obstructive pulmonary disease (COPD). Although singing has not yet been studied in NSCLC patients, the two conditions share overlapping symptoms and characteristics. Therefore, the present study aims to explore whether a singing-based intervention can help reduce symptom burden and improve physical function and QoL in NSCLC patients 6 to 18 months post-surgery. To test this, a multi-centre randomised controlled trial (RCT) will be conducted, comparing a singing intervention to usual care. Given that travel and distance often pose significant barriers to participation, the intervention will be delivered online.",[162,163],"Non-Small Cell Lung Cancer","Chronic Obstructive Lung Disease",[165,166,167,168,169,170,171,172,173,174],"lung cancer","rehabilitation","singing","online training","physical capacity","quality of life","symptom burden","airway physiology","physiology","six-minute walk test","2026-03-27",{"date":177,"type":41},"2026-04-02",{"date":179,"type":41},"2026-03-01",{"date":181,"type":21},"2027-10-01",{"name":47,"class":48},5,{"id":185,"slug":4,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":75},"100630013","NCT07482150","The Connect Trial: Connecting Hospital Patients to Alcohol Care","The Connect Trial: Connecting Hospital Patients to Alcohol Care - a Randomized Controlled Feasibility Trial","Inclusion Criteria:\n\n* Hospitalised or seen in an outpatient clinic at SUH Køge\n* Full-filling international classification of disease version 10: F102: alcohol dependence or F101: harmful alcohol use\n* Informed written consent\n* Being able to meet the AUD therapist in connection with a hospital visit with a health condition wholly or partly attributable to alcohol\n\nExclusion Criteria:\n\n* Ongoing specialized treatment for AUD\n* Not speaking Danish\n* Not living in the catchment area of Zealand University hospital\n* Age \\\u003C 18 years\n* Enrolled in the Zealand alcohol-related liver disease cohort study","99 Years",{"count":192,"type":21},60,[24],"The main objective of this pilot study is to assess feasibility of conducting a definitive RCT with concealed allocation, blinded outcome assessment and a 1:1 parallel group design of A) an invitation to meet an AUD therapist for up to 10 treatment sessions at the hospital in up to 6 months (intervention) compared to B) guidance on how to seek alcohol care in an AUD treatment centre in the community, outside of the hospital (control).",[196],"Alcohol Use Disorder",[198,199,200,201],"alcohol misuse treatment","inhospital alcohol care","pilot study","implementation study","2026-03-19",{"date":204,"type":41},"2026-03-24",{"date":206,"type":21},"2026-03-10",{"date":208,"type":21},"2031-09-01",{"name":47,"class":48},{"id":211,"slug":4,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":223,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":183},"100575179","NCT06768918","Digitizing Cancer Rehabilitation During and After Systemic Treatment: Feasibility Testing Implementation in South Baltic Countries","AMBeR eRehab","Inclusion Criteria:\n\n* Diagnosed with cancer (IDC: C00\\* - C97\\*)\n* Feasibility study 1 (early rehab): Participants should receive any systemic chemo\u002Fimmunotherapy preferably (but not necessarily) with a duration of 8 weeks or more. Recruitment should be at earliest convenience preferably (but not necessarily) within 4 weeks of treatment initiation.\n* Feasibility study 2 (rehab@home): Participants should preferably have completed chemotherapy\u002Fimmunotherapy no more than 6 months ago but may be receiving long-standing maintenance and life-prolonging chemo-\u002Fimmunotherapy.\n\nExclusion Criteria:\n\n\\- Cognitively unable to give consent to, or participate in, a digital rehabilitation programme as judged by project team staff.",{"count":217,"type":21},300,[24],"Background\n\nWith increasing cancer incidence and advanced cancer treatment, the growing population of cancer survivors increases the demand on health resources worldwide. Over the last 20 years, physical rehabilitation has reached recognition as an essential component of cancer care due its effect on physical function, side effects of treatment, and quality of life. However, highly specialized health care can result in longer distances to rehabilitation facilities. Also, a heavy appointment schedule for patients in treatment tends to complicate participation in rehabilitation. Telehealth has shown promise in increasing accessibility to services, also rehabilitation. However, barriers to participating in digitally delivered rehabilitation might exist, including lower e-health literacy and internet access in rural areas. The aim of this study is therefore, to examine the feasibility of implementing digitally supported rehabilitaiton in cancer care during and after treatment.\n\nMethodology In a multinational implementation study, the feasibility of implementation of digital rehabilitation will be tested in five South Baltic Countries (DK, SWE, GER, PL, LTU). Each site will host one feasibility trial for patients during cancer treatment and one for patients after, with n=30 patients in each fesibility trial (total n=300). The intervention will be needs-based, follow international guidelines, last from 8-16 weeks, and be delivered by trained Health Care Professionals (HCP's), either fully or partially digital. Mixed methods will be used to assess outcomes of reach, effectiveness, adoption, implementation and maintenance (RE-AIM).\n\nThrough the coordinated feasibility trials across five South Baltic countries, the investigators expect to learn about important factors in implementation of digitally delivered rehabilitation in different settings, cultures, and health systems. Finally, the investigators will bring recommendations for improving reach, implementation, and sustainability of digitally delivered rehabilitation across different settings.",[221,222],"Cancer Rehabilitation","Cancer",[224,225,226,227,228,229,230,231,232,233,234],"Remote physical rehabilitation","cancer rehabilitation","e-health","implementation","feasibility","acceptability","exercise","physiotherapy","home-based","oncology","usability","2026-03-09",{"date":237,"type":41},"2026-03-12",{"date":239,"type":41},"2024-10-03",{"date":241,"type":21},"2026-12-31",{"name":47,"class":48},{"id":244,"slug":4,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":22,"phases":252,"briefSummary":253,"conditions":254,"keywords":256,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},"100621046","NCT07365527","Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases","Tumor Response to Sonoporation: A Clinical Translational RCT of Contrast-enhanced Ultrasound Induced Changes in Tumor Microenvironment of Colorectal Liver Metastases","CEUSON","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* Ability to provide written informed consent\n* Histopathological confirmed colorectal adenocarcinoma\n* Scheduled for liver resection or ablation at the Rigshospital, or admitted to oncologic treatment due to colorectal liver metastases (CLM) at Zealand University Hospital\n* Presence of at least one CLM evaluable and accessible by CEUS\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Follow the conditions regarding fertility, pregnancy, or lactation:\n\n  * Women of childbearing potential (WOCBP) are defined as women ranging from the period of menarche till the post-menopausal period, unless permanently sterile (e.g. hysterectomy, bilateral salpingectomy and bilateral oophorectomy), Post-menopause is defined as no menses for 12 months without an alternative medical cause.\n  * WOCBP should use a secure and highly effective birth control (as stated in the \"Recommendations related to contraception and pregnancy testing in clinical trials\", version 1.1, section 4.1, from the Clinical Trials Facilitation and Coordination Group) during the entire period of the trial. In cases of uncertainty regarding pregnancy, pregnancy testing either as highly sensitive serum or urine pregnancy test will be used.\n\nExclusion Criteria:\n\n* Oncologic systemic treatment 2 weeks prior to inclusion\n* Prior treatment with an immune checkpoint inhibitor (e.g. anti-PD-L1, anti PD-1, or anti-PD-L2)\n* Inability to reliably distinguish the study metastasis from other hepatic metastases using CEUS\n* Systemic treatment with either corticosteroids (\\>10 mg daily prednisolone equivalents) or other immunosuppressive medications within 2 weeks prior inclusion. Inhaled or topical steroids and adrenal replacements doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n* Known history of human immunodeficiency virus (HIV), active or chronic hepatitis B, or C.\n* Pregnancy or lactation.\n* Confirmed dMMR positive primary tumors\n* Inability to comply with study protocol due to psychological, social, or logistical reasons.\n* Contraindications for CEUS:\n\n  * Known hypersensitivity to SonoVue® or any other ultrasound contrast agent\n  * Uncontrolled atrial hypertension\n  * Known right-to-left intracardiac shunt\n  * Severe pulmonary hypertension (SAP \\>90 mmHg)\n  * Adult respiratory distress syndrome.\n  * Known hypersensitivity to macrogols\n  * Unstable ischemic heart disease or acute coronary syndrome\n  * Severe lung disease, e.g. severe chronic obstructive lung disease",{"count":251,"type":21},48,[24],"This study is an investigator-initiated, randomized controlled trial enrolling patients with colorectal liver metastases. The objectives are to evaluate the safety and efficacy of contrast-enhanced ultrasound (CEUS)-mediated sonoporation as a potential therapeutic intervention and to investigate whether sonoporation can modulate the tumor microenvironment toward a more immune-active state",[255],"Liver Metastases From Colorectal Cancer",[257,258,259,260,261,262,263],"liver metastasis","CEUS","Sonoporation","Contrast enhanced ultrasound","colorectal cancer","liver metastases","tumor microenvironment","2026-02-24",{"date":266,"type":41},"2026-02-27",{"date":268,"type":41},"2026-02-25",{"date":270,"type":21},"2027-01-15",{"name":47,"class":48},2,{"id":274,"slug":4,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":280,"targetDuration":282,"studyType":59,"phases":4,"briefSummary":283,"conditions":284,"keywords":4,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":292,"leadSponsor":294,"locationsCount":4},"100621664","NCT07373561","Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors","Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors: An Inception Cohort Study (PICAS-DK)","PICAS-DK","Inclusion Criteria:\n\n* Adult patients ≥ 18 years of age\n* Admitted to the intensive care unit for ≥48 hours\n* Acutely admitted to the intensive care unit\n\nExclusion Criteria:\n\n* Patients with limited treatment\n* Foreign patients\n* Pregnant women\n* Patient with impaired cognitive function (e.g. dementia, intellectual disability)\n* Patient without Danish citizenship\n* Patient with limited proficiency in the Danish language",{"count":281,"type":21},800,"12 Months","The study aims to estimate the prevalence of post-intensive care syndrome (PICS) 12 months after ICU admission among adult ICU survivors in Denmark and to describe how this prevalence is distributed across the physical, cognitive, and mental health domains. By conducting follow-up assessments at 3, 6, and 12 months post-discharge, the study further seeks to determine the prevalence of PICS at each time point, characterise its temporal trajectory, and explore patients' symptom burden over time.\n\nResearch question\n\n* What is the prevalence of PICS and its specific components (physical, cognitive, and mental health domains) among ICU survivors 12 months after ICU admission?\n* How do the components of PICS evolve during the follow-up period (trajectory)?\n* What risk factors are associated with the development of PICS in ICU survivors?\n* Are there differences in PICS prevalence based on demographic or clinical characteristics (e.g., age, comorbidities, ICU length of stay)?\n\nThe hypothesis is that the prevalence of post-intensive care syndrome (PICS) in a Danish cohort of adult ICU survivors at 12 months will be approximately one third, defined as impairment in at least one of the three PICS domains (physical, cognitive, or mental health), measured using validated instruments with pre-specified cut-offs.",[285,286,287],"Post-Intensive Care Syndrome (PICS)","Symptom Burden","Intensive Care Unit (ICU) Patients","2026-01-28",{"date":290,"type":41},"2026-01-30",{"date":147,"type":21},{"date":293,"type":21},"2028-09-30",{"name":47,"class":48},{"id":296,"slug":4,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":303,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":75},"100622627","NCT07386080","Carbergoline for Antipsychotic Induced Hyperprolactinemia.","The Safety of Carbergoline Versus Placebo for Antipsychotic Induced Hyperprolactinemia: A Pragmatic, Randomised, Non-inferiority Trial With Blinded Outcome.","Inclusion Criteria:\n\n* receiveing antipsychotic treatment for at least 3 months for a schizophrenia spectrum disorder\n* Prolactin levels \\> URL\n* symptoms of hyperprolactinemia according to he UKU side effect scale (Udvalg for Klinisk Undersøgelser)\n* no suicide ideation at time of recruitment (≤ 2 Columbia-Suicide Serverity Rating Scale)\n\nExclusion Criteria:\n\n* patients that has previously responded unfavorably to treatment with a dopamine receptor agonist.\n* The use of recreational drugs that may give hyperprolactinemia.",{"count":302,"type":21},146,[304],"PHASE4","The goal of this clinical trial is to learn if cabergoline is safe to use in patients with antipsychotic-induced hyperprolactinemia in adults with scizophrenia. The main question it aims to answer :\n\nIs the severity of positive and negative symptoms affected by the use of cabergoline?\n\nResearchers will compare cabergolin to placebo to see if positive and negative symptoms are equel in both groups.\n\nParticipants will, in a blinded manor, take either placebo tablets or cabergoline for 12 weeks. The severity of positive and negative symptoms will be evaluated before and after the intervention in both groups.",[307],"Scizophrenia",[309,310],"prolactin","cabergoline","2026-01-27",{"date":313,"type":41},"2026-02-04",{"date":315,"type":21},"2026-05-01",{"date":317,"type":21},"2029-05-01",{"name":47,"class":48},{"id":320,"slug":4,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":22,"phases":327,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":75},"100560735","NCT06581016","Performance Characteristics and Technical Outcomes of Single-use vs. Reusable Gastroscopes Evaluated in the OR","Performance Characteristics and Technical Outcomes of Single-use Versus Reusable Gastroscopes Evaluated in the Operating Room in Acute, Subacute and Elective Patients","Inclusion Criteria:\n\n* Acute, subacute or elective gastroscopies in the operating theater\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* None",{"count":326,"type":21},700,[24],"The goal of this clinical trial is to investigate whether single-use gastroscopes are as good as reusable gastroscopes when used in the operation theater in all patients where gastroscopy in the operation theater is indicated. The main question it aims to answer is:\n\n\\- Is the technical success and performance characteristics the same for single-use and reusable gastroscopies?\n\nResearchers will compare single-use gastroscopes with reusable gastroscopes to see if the technical success and performance characteristics are the same in the to groups.\n\nParticipants will in the first period have gastroscopy with a single-use gastroscope. In the second period participants will have gastroscopy with a reusable gastroscope.",[330],"Upper Gastrointestinal Disorder",[332,333,334,335,336],"Gastroscopy","Upper endoscopy","Gastroscope","Single-use","Reusable","2026-01-07",{"date":339,"type":41},"2026-01-09",{"date":341,"type":41},"2024-09-01",{"date":343,"type":21},"2026-09-30",{"name":47,"class":48},{"id":346,"slug":4,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":22,"phases":354,"briefSummary":355,"conditions":356,"keywords":358,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":361,"lastUpdatePostDateStruct":362,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":183},"100507581","NCT05889247","Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer","Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer - a Randomized Interventional Study","PRELUCA","Inclusion Criteria:\n\n* Newly diagnosed, histologically verified, Non-Small Cell Lung Cancer (NSCLC)\n* Advanced or locally advanced disease without curative intended treatment options\n* Age \\> 18 years\n* Eastern Cooperative Oncology Group (ECOG) score of Performance Status (PS) 0-1\n* Measurable disease according to the iRECIST criteria version 1.1.\n* Eligible to first line immunotherapy (monotherapy)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Targetable alterations in EGFR, ALK or ROS-1\n* Other active cancers",{"count":353,"type":21},350,[24],"The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice.",[357],"Non-small Cell Lung Cancer Metastatic",[359,360],"liquid biopsy","treatment monitoring","2026-01-06",{"date":339,"type":41},{"date":364,"type":41},"2023-07-28",{"date":366,"type":21},"2032-06",{"name":47,"class":48},{"id":369,"slug":4,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":386,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":272},"100616343","NCT07304375","Effects of Exercise and Sleep on Motor Learning and Functional Abilities in Multiple Sclerosis","Effects of Aerobic Exercise and Daytime Sleep on Neurorehabilitation and Functional Abilities in Multiple Sclerosis: Evidence of Training the Brain in Neurorehabilitation","ExSiMS","Inclusion Criteria:\n\n* Competent individuals (aged 18-70) diagnosed with early relapsing-remitting MS\n* Expanded Disability Status Score, 1 \\\u003C EDSS \\\u003C 4.5\n* MRC muscle strength ≥ 4+ in the dominant hand\n\nExclusion Criteria:\n\n* Implanted devices, such as pacemakers or stimulators\n* Epilepsy or neuromuscular diseases","70 Years",{"count":377,"type":21},20,[24],"The ExSiMS study is a randomized, controlled crossover study including 20 individuals (18-70 years) diagnosed with relapsing remitting Multiple Sclerosis (MS) This project investigates, through behavioral and neurophysiological measurements, how aerobic exercise on an ergometer bike and sleep in the form of a nap and overnight sleep may enhance cortical motor skill learning evaluated by a complex hand motor skill test and thereby improve functional capacity in individuals with MS. Beyond the effect on motor skill learning, the project investigate the effect on electroencephalography (EEG) - electromyography (EMG) coherence.\n\nThe study hypothesizes that individuals with neurological conditions, such as multiple sclerosis (MS), may experience beneficial effects on specific motor rehabilitation through systematically planned cardiovascular exercise and sleep scheduling, due to positive impacts on memory consolidation.\n\nAims:\n\n* Investigate the brain's neurophysiological responses and memory effects following a training intervention and, separately, sleep, in the form of a power nap, in individuals with MS.\n* Examine whether these effects persist beyond the few days previously observed in healthy individuals by implementing a longer-term intervention.\n* Explore whether the training effect is influenced by disease activity in the brain, such as during relapses and during immunosuppressive treatment.\n* Assess whether the presence of abnormally reduced cognitive endurance (fatigue) affects the impact of the intervention involving exercise and sleep.\n\nThe study is based on documented positive effects of physical activity and sleep in both young and older adults, as well as in individuals recovering from stroke. The research thus offers promising perspectives for broader applications within neurorehabilitation, and particularly for MS, as the disease is associated with functional impairments. At the same time, both physical exercise and sleep represent meaningful interventions that should be thoughtfully integrated into rehabilitation strategies.",[381,382,383,384,385],"Exercise","Sleep","Motor Learning","Memory","Multiple Sclerosis",[387,388,382,389,383,384,390,391],"Aerobic Exercise","Daytime Sleep","Learning Ability","Cognitive Function","Neurorehabilitation","2026-01-05",{"date":394,"type":41},"2026-01-08",{"date":396,"type":41},"2025-12-01",{"date":398,"type":21},"2028-11-30",{"name":47,"class":48},{"id":401,"slug":4,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":408,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":418,"locationsCount":419},"100443407","NCT05053997","Navigate - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients","NAVIGATE - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients Through Nurse Navigation, Symptom Monitoring and Exercise: Study Protocol for a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Diagnosed with NSCLC at all stages regardless of treatment intension at the participating departments\n* Performance status ≤ 2\n* Vulnerable according to pre-defined criteria\n\nExclusion Criteria:\n\n* Severe untreated psychiatric disorder (e.g. psychosis) or cognitive problems (e.g. dementia) preventing informed consent\n* Not able to receive treatment\n* Not able to read and understand Danish -",{"count":407,"type":21},250,[24],"Half of patients with lung cancer face a limited life span of one-year survival, which is characterized by severe physical and psychological symptoms. Differences in stage, comorbidity but also treatment may explain a large proportion of the social inequality in lung cancer survival. Some vulnerable patients may not receive first line treatment as planned either due to poor performance status or if they are not able to adhere to treatment appointments. Knowing how to navigate the health system may be a barrier preventing vulnerable patients in receiving optimal treatment. The primary aim of this randomised, controlled trial is to test whether a nurse-led individually tailored program including systematic screening of symptoms using PROs and a physical training program will significantly improve a composite outcome of survival and quality of life as the primary outcome among vulnerable lung cancer patients compared with standard care. Secondary outcomes include adherence to cancer treatment, symptom burden and overall survival.",[411],"Lung Cancer","2025-12-20",{"date":414,"type":41},"2025-12-29",{"date":416,"type":41},"2022-03-01",{"date":241,"type":21},{"name":47,"class":48},6,{"id":421,"slug":4,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":183},"100598896","NCT07077447","The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract","DaBlaCa 23 - The European Collaborative Study on Upper Urinary Tract Urothelial Carcinoma","EuroCUT","Inclusion Criteria:\n\n* Patients with confirmed histopathology of UTUC\n* Age ≥ 18 years\n* Informed patient consent\n\nExclusion Criteria:\n\n* Patient not willing or able to give informed consent",{"count":428,"type":21},2500,"This is a study looking at how patients with a rare type of cancer in the pelvis and ureter of the kidney - called upper urinary tract urothelial carcinoma (UTUC) - is currently treated. The gold standard treatment of UTUC is the complete removal of the kidney, renal pelvis and ureter. The use of kidney-sparing surgery, which preserves the kidney while treating the cancer, was only considered for patients who were too frail to undergo kidney removal, had a solitary functioning kidney, or suffered from severe chronic kidney disease. Since 2018 international guidelines have incorporated kidney sparing surgery for all patients but only offered to patients that have been diagnosed with very low risk tumors to ensure the safety of the patients. The latest update of the UTUC Guidelines from the European Association of Urology has revised the criteria, so that certain features previously classified as high-risk are no longer considered high-risk on their own, provided the tumor otherwise appears benign. Nonetheless, ongoing research is essential to support this evolving approach and to further enhance the guidelines.\n\nKidney sparing surgery comprise of a strict follow up schedule that often demands supplemental surgeries under general anesthesia, which can cause strain on patients.\n\nPreservation of the kidney is important since a decrease in kidney function can result in increased risk of cardiovascular disease and death.\n\nThe main question we want to answer is:\n\nCan more patients with superficial non-invasive UTUC safely be treated with kidney-sparing surgery instead of the more aggressive surgery that removes the entire kidney and ureter without increasing the risk of the cancer coming back and while maintaining quality of life? Furthermore, we are interested in learning more about patients who later develop bladder cancer after treatment of UTUC (intravesical recurrences), the affection of kidney function over time and a subgroup of UTUC patients that are diagnosed with Lynch syndrome (a genetic condition that increases cancer risk and development of UTUC is the third most common cancer) where UTUC presents differently than other patients.\n\nParticipants Anyone diagnosed with UTUC can take part in the study. We will collect information from their medical records when they join and again after one, three, five, and ten years. Participants will also be asked to fill out quality-of-life questionnaires at the beginning of entering the study and at one, three and five years.",[431],"Upper Urinary Tract Urothelial Carcinoma",[433,431,434,435,436,437,438,439],"UTUC","Kidney Sparing Surgery","Prospective cohort study","Ureteroscopy","Radical nephroureterectomy","Lynch Syndrome","Endoscopic management of UTUC","2025-12-15",{"date":442,"type":41},"2025-12-22",{"date":444,"type":41},"2025-11-26",{"date":446,"type":21},"2040-06-30",{"name":47,"class":48},{"id":449,"slug":4,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":455,"targetDuration":282,"studyType":59,"phases":4,"briefSummary":456,"conditions":457,"keywords":462,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":476},"100606811","NCT07180407","The Post-ICU Pain Study","The Post-ICU Pain Study: a Multicenter, Prospective, Inception Cohort Study","PIP","Inclusion Criteria:\n\n* Adult ICU patients ≥18 years of age\n* Acute admission to the ICU\n* ICU length of stay of at least 48 hours\n\nExclusion Criteria:\n\n* Patients transferred from a non-participating ICU\n* Patients with pre-planned admission to the ICU e.g., following elective surgery\n* Patients unable to complete questionnaires, including those who are unable to understand or speak Danish, or patients with severe cognitive deficits.",{"count":281,"type":21},"BACKGROUND: ICU survivors may experience serious psychological, physical and cognitive impairments following ICU admission, collectively termed Post Intensive Care Syndrome (PICS). Persistent pain is an underrecognized component of PICS. Previous research has shown that persistent pain is a profound clinical challenge in ICU survivors, however, research demonstrates conflicting results. Furthermore, no studies have examined the prevalence of persistent pain in ICU survivors in a contemporary Danish ICU setting.\n\nOBJECTIVES: We aim to examine the clinical trajectory, risk factors, and pathophysiology of persistent pain in ICU survivors in Denmark.\n\nDESIGN AND SAMPLE SIZE: The study is designed as a multicenter, prospective, inception cohort study with clinical follow-up. Based on the pre-study sample size calculation, 800 patients will be included. Patients will be contacted by telephone 90 days and 180 days after ICU discharge, and a series of questionnaires regarding pain, sleep quality, affective state and quality of life will be completed. A subgroup of patients will undergo a detailed clinical examination including quantitative sensory testing between 180-365 days after ICU discharge.\n\nPOPULATION: Patients will be recruited from 4 Danish ICU departments. Inclusion criteria include adult patients (18 years of age), acute admission to the ICU, and an ICU admission of a minimum of 48 hours.\n\nOUTCOMES: The primary outcome is the prevalence of pain assessed by the Brief Pain Inventory (BPI) at 90 and 180 days after ICU discharge. Secondary outcomes include additional detailed descriptions of pain and daily activity, sleep quality, affective state, quality of life, treatment- and patient-related risk factors, and biomarkers associated with development of persistent pain.\n\nSubstudies:\n\n\\- QST substudy: 80 participants (40 with pain and 40 without pain) recruited from the main cohort will undergo Quantative Somatosensory Testing (QST). The objectives are first, to delineate somatosensory profiles of ICU survivors with and without pain, and second, to examine the presence of neuropathic pain in ICU survivors.",[458,459,460,461],"Chronic Pain","Post Intensive Care Unit Syndrome","Quality of Life","Pain Disorder",[463,464,465,466,467],"intensive care units","chronic pain","sleep disorder","anxiety and depression","icu survivors","2025-11-29",{"date":470,"type":41},"2025-12-02",{"date":472,"type":41},"2025-09-23",{"date":474,"type":21},"2027-06",{"name":47,"class":48},4,{"id":478,"slug":4,"hasResults":11,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":22,"phases":485,"briefSummary":486,"conditions":487,"keywords":492,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":75},"100554029","NCT06493773","Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial","Alcohol Misuse Treatment Delivered in the Hepatology Clinic to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial","Inclusion criteria\n\n* Age \\> 18 years\n* Newly diagnosed alcohol-related liver disease, defined as within six months from baseline visit.\n* A liver stiffness above 8.0 kPa with 10 successful measurements and an interquartile range of less than 30% as assessed with transient elastography.\n* Excessive alcohol consumption defined as \\>7 units\u002Fweek for women and \\>14 units\u002Fweek for men within the previous year.\n* The patient is able to understand the purpose of the study and give informed oral and written consent to participate.\n\nExclusion criteria\n\n* Not enough proficiency in Danish to participate in interviews and questionnaires.\n* Pregnancy\n* Ongoing specialized AUD treatment. Self-help groups and AUD counselling at general practitioners are not counting as specialized AUD treatment in this study.",{"count":484,"type":21},221,[24],"To evaluate the efficacy of systematically offering newly diagnosed ALD patients to AUD treatment, in the hepatology clinic, on alcohol abstinence after 6 months. The investigators will conduct a randomized controlled superiority trial with parallel group design, hypothesis blinding and blinded outcome assessment comparing A) a offer to specialized AUD treatment (intervention) and B) standard care (control). Existing observational cohort ALD members will contribute to the control group in addition to the randomized controls. The primary outcome is abstinence throughout the last 30 days assessed 6 months after randomization.",[488,196,489,490,491],"Liver Diseases, Alcoholic","Treatment Adherence","Alcoholism","Liver Disease; Alcohol-Related",[493,494,495,496,497],"Alcoholic liver disease","Alcohol use disorder","Alcohol treatment","randomized clinical trial","hepatology clinic","2025-11-14",{"date":500,"type":41},"2025-11-18",{"date":502,"type":21},"2025-11-15",{"date":504,"type":21},"2029-04-01",{"name":47,"class":48},{"id":507,"slug":4,"hasResults":11,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":22,"phases":514,"briefSummary":515,"conditions":516,"keywords":521,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":75},"100563450","NCT06616324","Virtual Reality to Reduce Pain and Anxiety During Extracorporeal Shock Wave Lithotripsy","Virtual Reality: An Innovative Approach to Reduce Pain and Anxiety During Extracorporeal Shock Wave Lithotripsy - A Randomized Controlled Trial","Inclusion Criteria:\n\n* Scheduled for ESWL at Region Zealand\n* Age of 18 or above\n* Ability to understand the trial protocol, risks, and benefits and provide signed informed consent\n\nExclusion Criteria:\n\n* Inability to read and understand Danish.\n* Uncooperativeness (as judged by investigators)\n* Claustrophobia or fear of small spaces\n* Disorders that prevent the person from wearing a VR device\n* Highly visually or auditive impaired",{"count":513,"type":21},72,[24],"The objective of this study is to evaluate the impact of intraprocedural Virtual Reality (VR) as a non-pharmacological intervention for mitigating anxiety and pain during Extracorporeal Shock Wave Lithotripsy (ESWL). The hypothesis is that VR can effectively reduce both pain and anxiety levels in patients by diverting their cognitive focus, potentially leading to a decrease in pharmacological intervention requirements.\n\nThe primary outcome is pain at energy level 900 during ESWL for the intervention and the control group.\n\nThe secondary outcomes are as follows:\n\n* Type and dose of analgesia\n* Conductance scores\u002Fvalues\n* Anxiety levels\n* Patient satisfaction\n* Procedure duration\n* Adverse events\n\nParticipants will be randomized into either the intervention or control group. Both groups will undergo ESWL according to standard treatment; however, the intervention group will wear a Virtual Reality headset and noise-cancelling headphones during the procedure, while the control group will not",[517,518,519,520],"Anxiety","Pain","Virtual Reality","Lithotripsy",[519,518,517,522,523,524,520,525],"VR","ESWL","Extracorporeal Shock Wave Lithotripsy","Non-pharmacological","2025-09-22",{"date":472,"type":41},{"date":529,"type":41},"2024-10-24",{"date":531,"type":21},"2025-10-01",{"name":47,"class":48},{"id":534,"slug":4,"hasResults":11,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":17,"minAge":113,"maxAge":540,"enrollmentInfo":541,"targetDuration":4,"studyType":22,"phases":542,"briefSummary":543,"conditions":544,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":553,"locationsCount":272},"100548101","NCT06416618","Surgical Versus Non-surgical Treatment of Displaced Proximal Humerus Fracture in Adults Aged 50 to 65 Years","Surgical Versus Non-surgical Treatment of Displaced Proximal Humerus Fracture in Adults Aged 50 to 65 Years: a Pragmatic Randomized Controlled Trial","PHF50-65","Inclusion Criteria:\n\n* Patients aged between 50 and 65 years with a displaced PHF assessed to be constructible by the treating surgeon after a low-energy trauma will be considered for eligibility.\n* Patients should be cognitively capable of answering the follow-up questionnaires.\n\nExclusion Criteria:\n\n* The patient does not understand written and spoken native language (Danish or Finnish\u002FSwedish)\n* Inability to give informed consent\n* Fractures assessed to be unreconstructedly by the treating surgeon\n* Isolated tuberosity fracture, fracture dislocations, open fractures, and fractures with involvement of the articular surface\n* Less than 25% contact between head fragment and metaphysis\u002Fdiaphysis measured at two perpendicular radiographs at two weeks.\n* Pathological fractures or previous fractures in the same proximal humerus\n* Concomitant fractures, which could influence the outcome\n* Paralysis in upper extremity","65 Years",{"count":192,"type":21},[24],"The goal of this clinical trial is to study whether surgery results in better functional outcomes than non-surgical treatment among patients aged 50-65 with a displaced proximal humerus fracture.\n\nThe main questions it aims to answer are:\n\n• Does osteosynthesis result in better patient-reported functional outcomes compared to non-surgical treatment at 12 months follow-up?\n\nAim is also to characterize the patient group aged 50-65 regarding fracture morphology, osteoporosis, and clinical frailty scale.\n\nThe study compare operation with either plate or nail fixation to non-surgical treatment.\n\nParticipants will:\n\n* Receive either surgical treatment or non-surgical treatment.\n* At 6 months, 1 year, and 2 years, the patient will answer two short questionnaires (Oxford Shoulder Score and Eq-5D-3L).\n\nThe primary outcome will be Oxford Shoulder Score at 12 months. The secondary outcome will be OSS at 6 and 24 months and EQ-5D-3L score measured at the same time-points. Adverse events and conversion to surgery will be registered. OSS and EQ-5D-3L will be completed just before the 6 months visit.",[545,546],"Proximal Humeral Fracture","Shoulder Fractures","2025-09-11",{"date":549,"type":41},"2025-09-18",{"date":551,"type":41},"2024-05-15",{"date":73,"type":21},{"name":47,"class":48},{"id":555,"slug":4,"hasResults":11,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":559,"eligibilityCriteria":560,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":22,"phases":563,"briefSummary":564,"conditions":565,"keywords":570,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":75},"100592388","NCT06992778","Effectiveness and Acceptability of Remote Fine-Tuning of Hearing Aids in Danish Adults","Exploring the Effectiveness and Acceptability of Remote Fine-Tuning of Hearing Aids in Danish Adults: A Non-blinded, Non-inferiority Randomized Controlled Trial With an Embedded Qualitative Study","EARFit","Inclusion Criteria:\n\n* Adult patients with hearing loss who desire HA treatment (+18 of age).\n* Danish language skills both written and oral.\n* Acquisition of digital proficiency in terms of being familiar with operating a smartphone, including navigating menus, opening and closing apps, and interacting with the touchscreen with capabilities for audio and video calls.\n* Access to a smartphone that are compatible with manufacturers' system requirements.\n* Access to a stable network connection on the mobile device, with either Wi-Fi or mobile data.\n\nExclusion Criteria:\n\n* Patients with tinnitus requiring treatment or scoring more than 58 in the 'Tinnitus Handicap Inventory' (THI) grading system.\n* Patients with Ménière disease, due to its complications and symptoms as dizziness, balance problems and fluctuating hearing loss, that can affect the HA treatment.\n* Patients who will receive in-the-ear (ITE) hearing aids, due to potential limitations in connectivity for remote fine-tuning.\n* Patients which are recommended\u002Foffered unilateral HA treatment.",{"count":562,"type":21},120,[24],"The aim of this clinical trial is to evaluate the effectiveness and user satisfaction of remote fine-tuning of hearing aids compared to traditional face-to-face adjustments. The main questions aims to answer:\n\n\\- Are hearing aid outcomes (self-reported and objective) similar when using remote fine-tuning compared to face-to-face adjustments?\n\nResearchers will compare remote fine-tuning (using a smartphone app) to traditional face-to-face fine-tuning sessions in a clinical setting.\n\nParticipants will:\n\n* Be randomized to either the remote fine-tuning group (intervention group) or the face-to-face adjustment group (control group).\n* Attend five scheduled consultations over a 3-month period, including baseline measurements, hearing aid fittings, and follow-up visits.\n\nParticipants in the remote fine-tuning group will:\n\n\\- Set up and use a hearing aid manufacturer's smartphone app to complete fine-tuning sessions from home.\n\nParticipants in the face-to-face group will:\n\n\\- Visit the clinic for in-person fine-tuning appointments.\n\nData will be collected through questionnaires (e.g., SSQ-12, IOI-HA, and COSI) and objective measures such as the Speech Intelligibility Index (SII) and speech comprehension in noise (DS-FF). Additional qualitative data will be gathered from interviews with participants in the remote fine-tuning group.",[566,567,568,569],"Hearing Aid","Telehealth","Hearing Aid Fitting","Effectiveness",[571,572,573,574,575],"Remote fine-tuning","Teleaudiology","Randomized controlled trial (RCT)","Hearing aids","Denmark","2025-08-13",{"date":578,"type":41},"2025-08-14",{"date":580,"type":41},"2025-05-27",{"date":582,"type":21},"2026-03-30",{"name":47,"class":48},{"id":585,"slug":4,"hasResults":11,"nctId":586,"briefTitle":587,"officialTitle":587,"acronym":4,"eligibilityCriteria":588,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":589,"targetDuration":4,"studyType":22,"phases":591,"briefSummary":592,"conditions":593,"keywords":594,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":75},"100575347","NCT06771102","Performance Characteristics and Technical Outcomes of Single-use Gastroscopes Used Bedside Versus Reusable Gastroscopes Used in the Endoscopy Unit Evaluated in Subacute Patients","Inclusion Criteria:\n\n* Patients of any gender, 18 years of age or older admitted to the acute section of the surgical department (Kir2) at Zealand University Hospital referred to early EGD without general anesthesia.\n\nExclusion Criteria:\n\n* ASA-score of 4 or higher\n* Unstable patient\n* Suspicion of ventricular retention\n* Suspicion of active bleeders\n* Need for expert endoscopist to perform the procedure, e.g. stenting\n* Patients \\\u003C 18 years of age",{"count":590,"type":21},180,[24],"The aim of this study is to investigate whether single-use gastroscopes used bedside can reduce the time from indication to procedure compared with re-usable gastroscopes used at the endoscopy unit in patients referred to a subacute gastroscopy.\n\nParticipants in the first period will be scheduled for gastroscopy with a re-usable gastroscope in the endoscopy unit, whereas participants during the second period will have a gastroscopy performed at the ward (bed-side) with a single-use gastroscope.",[330],[332,333,334,335,336,595],"Bedside","2025-06-10",{"date":598,"type":41},"2025-06-15",{"date":600,"type":41},"2025-01-13",{"date":602,"type":21},"2027-04",{"name":47,"class":48},{"id":605,"slug":4,"hasResults":11,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":610,"enrollmentInfo":611,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":612,"conditions":613,"keywords":616,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":75},"100522313","NCT06080997","Patients' Expectations Before Spinal Surgery","Patients' Expectations Before, and Their Experiences After Spinal Surgery, Regarding Pain, Rehabilitation and Quality of Life","Inclusion Criteria:\n\nPatients undergoing elective spinal surgery. Patients able to read and understand Danish.\n\nExclusion Criteria:\n\nPatients with cognitive deficits, such as dementia. Patients with alcohol and drug dependence.","100 Years",{"count":217,"type":21},"With this study the investigators want to perform a prospective observational cohort study at Zealand University Hospital, Koege, Denmark.\n\nThe purpose of this study is twofold:\n\n1. to investigate how expectations predict patients' pain, rehabilitation and quality of life after spinal surgery.\n2. to explore the patients' expectations before, and their experiences after, spinal surgery regarding pain, rehabilitation and quality of life.",[614,615,518,460],"Expectations","Surgery",[614,518,617,618],"Rehabilitation","Quality of life","2025-02-17",{"date":621,"type":41},"2025-02-18",{"date":623,"type":41},"2024-01-01",{"date":625,"type":21},"2026-11-30",{"name":47,"class":48},{"id":628,"slug":4,"hasResults":11,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":632,"eligibilityCriteria":633,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":634,"targetDuration":4,"studyType":22,"phases":636,"briefSummary":637,"conditions":638,"keywords":646,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":654,"completionDateStruct":656,"leadSponsor":658,"locationsCount":75},"100512377","NCT05951660","Sex, Psychopharmacology, and Diabetes","The Effect of Targeted Education on Number, Severity, and Perception of Sexual Side Effects of Patients Suffering From Schizophrenia and Diabetes or Prediabetes.","SECRET","Inclusion Criteria:\n\n* Age ≥ 18 years\n* A diagnosis in the schizophrenic spectrum (ICD10 F2x)\n* One of the following:\n\n  1. A diagnosis of diabetes (ICD10 E10x, E11x, E12x, E13x, 14x)\n  2. A current or previous prediabetes defined as an HbA1c between 39-47 mmol\u002Fmol (both included) measured in at least two blood samples collected with ≥3 months intervals as part of the patient's routine clinical monitoring\n  3. Obesity defined as a Body-Mass Index (BMI) ≥30 kg\u002Fm2\n* Ongoing treatment with at least one antipsychotic agent\n* A SD that can be rated using Changes in Sexual Function Questionnaire-14 (CSFQ-14)\n\nExclusion Criteria:\n\n* Incapacitated or subject to mental health probation\n* Unable to speak danish",{"count":635,"type":21},256,[24],"The term sexual (SD) dysfunction covers conditions that prevent people from having a satisfactory sex life. SD is a frequent and sometimes debilitating complication of mental illness and a known adverse reaction to psycho-pharmacological treatment. SD is also associated with diabetes, a common somatic comorbidity in psychiatric patients. SD is associated with both reduced quality-of-life and reduced treatment adherence, yet SD is far too rarely addressed between the patient and the healthcare professional in clinical consultations.\n\nThe purpose of the study is to investigate whether targeted education of patients with schizophrenia and diabetes\u002Fprediabetes and\u002For their healthcare professionals in causes and management of SD:\n\n* Increases the number of systematic examinations of sexual side effects,\n* Causes changes in the psycho-pharmacological treatment, and\n* Reduces the severity or perception of sexual side effects.\n\nThe study is a multicenter Randomized Controlled Trial (RCT) with four arms, in which the educational intervention is provided to patients, healthcare professionals, or both groups. The effect of the educational intervention is compared to a non-educated control group. The study is expected to include 192 patients recruited from 16 assertive community treatment centers evenly distributed in four Danish regions.\n\nThe study is part of an interdisciplinary project named SECRET. The educational intervention was developed in an ethnographic pre-study incorporating stakeholder engagement. Parallel to the present RCT, an ethnographic field study will be carried out to broaden the perspective on the effects of the intervention.",[639,640,641,642,643,644,645],"Schizophrenia","Schizophrenia Spectrum and Other Psychotic Disorders","Diabetes Mellitus","PreDiabetes","Sexual Dysfunction","Drug-Related Side Effects and Adverse Reactions","Education",[647,648,649,650],"Randomized Controlled Trial","Treatment Adherence and Compliance","Antipsychotic Agents","Patient Education as Topic","2025-02-07",{"date":653,"type":41},"2025-02-11",{"date":655,"type":41},"2023-08-24",{"date":657,"type":21},"2025-07-31",{"name":47,"class":48},{"id":660,"slug":4,"hasResults":11,"nctId":661,"briefTitle":662,"officialTitle":662,"acronym":4,"eligibilityCriteria":663,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":664,"targetDuration":666,"studyType":59,"phases":4,"briefSummary":667,"conditions":668,"keywords":671,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":75},"100570739","NCT06711159","SLEEPINESS - a Search for a Biomarker of Excessive Daytime Sleepiness in Severe Obstructive Sleep Apnoea - An Explorative Study","Inclusion Criteria:\n\nFor a subject to be eligible, all inclusion criteria must be answered \"yes\":\n\n1. Age ≥18 years\n2. Subjects must be diagnosed with Severe Obstructive Sleep Apnea (AHI \\> 30) and have not yet started any form of PAP (positive airway pressure) treatment.\n3. ESS score must be above 10 at the time of inclusion.\n\nExclusion Criteria:\n\nFor a subject to be eligible, all exclusion criteria must be answered \"no\":\n\n1. Known severe neurological or psychiatric diseases.\n2. Known congestive heart failure, chronic renal failure, liver failure, malignancy, severe pulmonary disease.\n3. Considerable use of alcohol.\n4. Medication judged by investigator to influence sleep\u002Fwake regulation to such a degree that data quality will be compromised.\n5. Has cochlear implants.\n6. Involved in therapies with medical devices that deliver electrical energy into the area around the implant.\n7. Is at high risk of surgical complications, such as active systemic infection and haemorrhagic disease.\n8. Are unable (i.e. mentally or physically impaired patient), or do not have the necessary assistance, to properly operate the device system.\n9. Has an infection at the site of device implantation.\n10. Operates MRI scanners.\n11. Has a profession\u002Fhobby that includes activity imposing extreme pressure variations (e.g. diving or parachute jumping). NB: diving\u002Fsnorkelling is allowed to 5 metres depth.\n12. Has a profession\u002Fhobby that includes activity imposing an unacceptable risk for trauma against the device or the site of implantation (e.g. martial art or boxing).\n13. Other known diseases or conditions, judged by investigator to influence sleep to such a degree that data quality will be compromised.\n14. Incapable, judged by the investigator, of understanding the participant instruction or who are not capable of carrying through the investigation.\n15. Pregnancy or intention to become pregnant within the next 12 months.",{"count":665,"type":21},15,"12 Weeks","Study aim:\n\nThis study aims to use a new brainwave monitoring device that meassure brainwaves 24 hours a day to create better understanding of sleep-wake interplay as a biomarker for excessive daytime sleepiness because of obstructive sleep apnea.\n\nStudy Method, Design, and Procedures Patients with sleep apnea referred to the Sleep Clinic at the Department of Ear, Nose, Throat, and Jaw Surgery in Køge for CPAP treatment, who also experience severe daytime sleepiness, will be offered participation in this study. The goal is for 15 participants to complete the entire protocol.\n\nProcedure Overview Initial Sleep Assessment: The study begins with an in-depth sleep assessment through polysomnography (PSG) followed by a Multiple Sleep Latency Test (MSLT).\n\nPSG: This sleep study evaluates sleep structure, confirms sleep apnea, and rules out other sleep disorders.\n\nMSLT: This test measures the brain's tendency to fall asleep during the day. Additional Home-Based Sleep Studies: Participants will undergo two more PSG studies in their homes.\n\nEEG Monitoring: After the initial assessments, participants will have a small EEG electrode implanted to monitor brain activity.\n\nThe implant, a CE-certified device called 24\u002F7 EEG™ SubQ, will be inserted under local anesthesia by an experienced surgeon.\n\nOnce post-surgery swelling subsides (after about 7-10 days), continuous EEG monitoring will begin, where participants connect an external data storage device during the day. The device records for 12 weeks, and CPAP treatment begins around the 6-week mark.\n\nAfter 12 weeks, the EEG device is removed, and the study ends. Aditional Data Collection (Optional)\n\nDuring the 12 weeks of EEG recording, participants are asked to report:\n\nSleep Diary: Log daytime sleep episodes, including planned naps and unintended naps.\n\nQuestionnaires and Tests: Complete daily questionnaires about fatigue symptoms and perform a brief attention and reaction test. These tasks take 3-10 minutes each day and are accessible via smartphone or tablet.\n\nInterviews and Movement Tracking: Participants may also be invited to interviews on how sleepiness affects their daily life and asked to wear a motion-tracking watch to monitor activity.",[669,670],"Obstructive Sleep Apnea (OSA)","Excessive Daytime Sleepiness",[672,673,674,675],"Excessive daytime sleepiness","Ultra long-term EEG","Obstructive Sleep Apnea","CPAP","2024-11-25",{"date":678,"type":41},"2024-12-02",{"date":680,"type":41},"2024-10-11",{"date":682,"type":21},"2025-12-31",{"name":47,"class":48},{"id":685,"slug":4,"hasResults":11,"nctId":686,"briefTitle":687,"officialTitle":688,"acronym":689,"eligibilityCriteria":690,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":691,"targetDuration":4,"studyType":22,"phases":693,"briefSummary":694,"conditions":695,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":697,"lastUpdatePostDateStruct":698,"startDateStruct":700,"completionDateStruct":702,"leadSponsor":704,"locationsCount":75},"100475392","NCT05470335","Nurse-led Sheath Insertion in Cardiac Patients","Patient Comfort, Success Rate, Procedure Time and Complications During Sheath Insertion by Nurses and Physicians in Connection With Invasive Examination and Treatment of Cardiac Patients","NUSHI","Inclusion Criteria:\n\n* patients suspected of having coronary artery disease\n* with normal puls oxymetry on the right hand\n* understands patient information and accepts to participate\n\nExclusion Criteria:\n\n* under consideration for cardiac valve replacement\n* systolic blood pressure persistently \\>180 mmHg",{"count":692,"type":21},1000,[24],"The aim of project NUSHI is to elucidate, that radial sheath insertion can be performed by nurses and physicians with the same level of comfort and safety.",[696],"Coronary Artery Disease","2024-08-05",{"date":699,"type":41},"2024-08-06",{"date":701,"type":41},"2022-09-01",{"date":703,"type":21},"2026-09",{"name":47,"class":48},""]